Advair Diskus 250/50 is also indicated to reduce exacerbations in patients with a history of exacerbations. Advair Diskus 250/50 is the only approved strength for COPD because an efficacy advantage of ...
GlaxoSmithKline plc (GSK) today announced results from the 'LABA' (long acting beta 2-agonist) safety study, AUSTRI(SAS115359). The study compared Advair ® Diskus ®, a combination of the LABA, ...
Fluticasone propionate 50mcg/inh, 100mcg/inh, 250mcg/inh; dry pwd for inhalation; blisters with inhalation device; contains lactose monohydrate. as a disposable orange plastic inhaler containing a ...
GSK and Theravance announce positive results from studies comparing ANORO™ ELLIPTA™ with SERETIDE® DISKUS®and ADVAIR® DISKUS® in patients with COPD GlaxoSmithKline plc (LSE/NYSE: GSK) and Theravance, ...
Advair 250/50 Now the Only Treatment Approved to Both Reduce Exacerbations and Improve Lung Function RESEARCH TRIANGLE PARK, N.C., May 1 -- Late yesterday the U.S. Food and Drug Administration ...
Advair Diskus 250/50 is also indicated to reduce exacerbations in patients with a history of exacerbations. Advair Diskus 250/50 is the only approved strength for COPD because an efficacy advantage of ...
RESEARCH TRIANGLE PARK, N.C., May 1 Lateyesterday the U.S. Food and Drug Administration approved Advair Diskus(R)250/50 (fluticasone propionate 250 mcg and salmeterol 50 mcg inhalationpowder) for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results